Watch PTHS. Know when insiders buy.
One email the day a filing lands. Free.
PTHS
Pelthos Therapeutics Inc.
22.19
−0.21 −0.94%
USD · close Sep 25
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
31
FLAG · shorts 31
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $169.9MP/E —DIV YIELD —FCF YIELD —REV TTM $43.3MNET INCOME −$86.4MNET CASH —52W 18.19 – 37.42SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $15.6M | — | 76.9% | −$17.3M | −$23.4M | — | -6.62 | −$7.7M | $2K | −$7.7M | Aug 13 |
| Q1 2026 · Mar 31 | $10.9M | — | 84.7% | −$13.1M | −$25.1M | — | -7.57 | −$13.1M | $194K | −$13.3M | Aug 13 |
| Q4 2025 · Dec 31derived | $9.4M | — | 82.2% | −$12M | −$21.7M | — | -8.08 | −$6.3M | — | — | Mar 19 |
| Q3 2025 · Sep 30 | $7.4M | — | 68.7% | −$15.4M | −$16.2M | — | -5.30 | −$15.3M | — | — | Nov 13 |
| Q2 2025 · Jun 30 | $0 | — | — | −$3.2M | −$3.4M | — | -5.29 | −$447K | $0 | −$447K | Aug 13 |
| Q1 2025 · Mar 31 | $0 | — | — | −$1.8M | −$2M | — | -3.21 | −$632K | $0 | −$632K | Aug 13 |
| Q4 2024 · Dec 31derived | — | — | — | −$1.8M | −$1.9M | — | -3.15 | −$670K | — | — | Mar 19 |
| Q3 2024 · Sep 30 | — | — | — | −$2M | −$1.7M | — | -2.93 | −$178K | — | — | Nov 13 |
| Q2 2024 · Jun 30 | — | — | — | −$1.8M | −$1.8M | — | -3.07 | −$3M | — | — | Nov 13 |
| Q1 2024 · Mar 31 | — | — | — | −$1.9M | −$2.6M | — | -0.55 | −$2M | — | — | Nov 13 |
| Q4 2023 · Dec 31derived | — | — | — | −$3.9M | −$4M | — | -2.54 | −$357K | — | — | Mar 27 |
| Q3 2023 · Sep 30 | — | — | — | −$1.3M | −$1.4M | — | -1.44 | −$257K | — | — | Nov 13 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $16.8M | 76.3% | −$32.4M | −$43.3M | -257.9% | -23.04 | −$22.6M | $99K | −$22.7M | $0 | — |
| FY2024 · to Dec 31 | $0 | — | −$7.6M | −$8M | — | -14.27 | −$5.8M | $0 | −$5.8M | $75K | — |
| FY2023 · to Dec 31 | — | — | −$6.9M | −$7.4M | — | -5.78 | −$981K | — | — | — | — |
| FY2022 · to Dec 31 | — | — | −$2.3M | −$2.5M | — | 5.65 | −$1.6M | — | — | — | — |
Every number comes from Pelthos Therapeutics Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.